Chesterford tenants, Isogenica have announced the appointment of Dr Chris Ullman as CEO with effect from September 29th 2014, following the decision by Dr Kevin Matthews to leave Isogenica to join a publicly listed polymer technology company.
Dr Ullman has been with Isogenica since 2002 and was promoted into the CSO role in 2009. Over the last five years he has been instrumental in developing Isogenica’s strategy, taking the lead role in driving Isogenica’s technologies and has worked closely with Isogenica’s customers and partners.
“Dr Ullman has worked closely with Dr Matthews over the last five years and has been at the heart of delivering a fundamental change in the capability and direction of the business. I am sure that Chris will be successful in further developing Isogenica to provide technologies and technology capabilities that are valued by its pharma and biotech partners and academic collaborators” said Jan-Olof Lundin, Chairman of Isogenica.
For more information about Isogenica please click here.